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BACKGROUND: Recently, the management of head and neck squamous cell carcinoma (HNSCC) has focused considerable attention on
biomarkers, which may influence outcomes. Tests for human papilloma infection, including direct assessment of the virus as well as an
associated tumour suppressor gene p16, are considered reproducible. Tumours from familial melanoma syndromes have suggested
that nuclear localisation of p16 might have a further role in risk stratification. We hypothesised p16 staining that considered nuclear
localisation might be informative for predicting outcomes in a broader set of HNSCC tumours not limited to the oropharynx, human
papilloma virus (HPV) status or by smoking status.
METHODS: Patients treated for HNSCC from 2002 to 2006 at UNC (University of North Carolina at Chapel Hill) hospitals that had
banked tissue available were eligible for this study. Tissue microarrays (TMA) were generated in triplicate. Immunohistochemical
(IHC) staining for p16 was performed and scored separately for nuclear and cytoplasmic staining. Human papilloma virus staining was
also carried out using monoclonal antibody E6H4. p16 expression, HPV status and other clinical features were correlated with
progression-free (PFS) and overall survival (OS).
RESULTS: A total of 135 patients had sufficient sample for this analysis. Median age at diagnosis was 57 years (range 20–82), with 68.9%
males, 8.9% never smokers and 32.6% never drinkers. Three-year OS rate and PFS rate was 63.0% and 54.1%, respectively. Based on
the p16 staining score, patients were divided into three groups: high nuclear, high cytoplasmic staining group (HN), low nuclear, low
cytoplasmic staining group (LS) and high cytoplasmic, low nuclear staining group (HC). The HN and the LS groups had significantly
better OS than the HC group with hazard ratios of 0.10 and 0.37, respectively, after controlling for other factors, including HPV
status. These two groups also had significantly better PFS than the HC staining group. This finding was consistent for sites outside the
oropharynx and did not require adjustment for smoking status.
CONCLUSION: Different p16 protein localisation suggested different survival outcomes in a manner that does not require limiting the
biomarker to the oropharynx and does not require assessment of smoking status.
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Head and neck squamous cell carcinoma (HNSCC) diagnoses
constitute B3–5% of all cancers with an estimate of 49 000 new
cases and 11 000 deaths in 2010 in the United States (National
Cancer Institute, 2005; Jemal et al, 2010). Recent epidemiological
data suggest an increasing incidence rate among younger people
who are often nonsmokers and nondrinkers (Schantz and Yu,
2002; Shiboski et al, 2005; Curado and Hashibe, 2009; Marur et al,
2010; Patel et al, 2011), which are frequently attributable to human
papilloma virus (HPV) infection (Franceschi et al, 1996; El-Mofty
and Lu, 2003; Dahlstrand et al, 2004; Furniss et al, 2007;
Chaturvedi et al, 2011). Human papilloma virus-positive tumours
are typically found in the oropharynx and have better response
to treatment (Fakhry et al, 2008) and better disease outcome
(Hafkamp et al, 2008; Ang et al, 2010). There is significant
consensus that knowledge of patient HPV status will increasingly
have a role in the management of this disease.
However, assessment of risk in the context of HPV infection has
ongoing challenges. Perhaps chief among these is the fact that the
diagnostic tests for the infection have limitations, and second, that
smoking appears to degrade the favourable outcomes in patients
with HPV-associated cancers for reasons that are unclear. There
are two broad categories of assays for HPV. In the first category
are tests for the virus itself including PCR, IHC and in situ
hybridisation. Alternatively, HPV status can be assessed indirectly
through the p16 biomarker, which is generally highly expressed
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in the setting of HPV infection. Detection of HPV directly suffers
from a variety of limitations including both false positives and false
negatives depending on the setting for reasons that have been
extensively reviewed (Shroyer and Greer, 1991; Ha et al, 2002;
Termine et al, 2008; Stevens et al, 2011). Recently, large clinical
trials have addressed the false positive concern primarily by
assessing HPV only in the oropharynx, assuming that most positive
tests outside the oropharynx would be false positives. The concern
for false negatives has frequently been addressed with the addition
of the biomarker p16, which is highly correlated with HPV infection
because it is generally believed that HPV in situ hybridisation is less
sensitive and more specific than p16 staining (Begum et al, 2007;
Schache et al, 2011; Stevens et al, 2011). In fact, recent studies have
consistently shown favourable correlation between the two bio-
markers, with nearly all HPV-positive samples also staining for p16
(Begum et al, 2007). Interestingly, however, there is also a consistent
pattern of p16-positive, HPV-negative oropharynx tumours in the
range of B20% (Ang et al, 2010). Strikingly, however, p16-negative,
HPV-positive tumours are rare. Most commonly, the p16-positive,
HPV-negative case has been attributed to a failed test of HPV, such
as the presence of an HPV subtype not assessed by the assay. Such
an explanation fails to address the fact that p16 is frequently
positive in HNSCC outside the oropharynx, where HPV infection
has generally been classified as a rare event. Interestingly, p16
positivity within the oropharynx appears to be at least as good a
marker of favourable outcome, independent of whether samples
also stained for HPV (Reimers et al, 2007; Ang et al, 2010). Yet
outside the oropharynx, p16 has only infrequently been reported as
a favourable marker (Harris et al, 2010b).
In addition to the complex story involving tumour site
(oropharynx) and the biomarkers p16 and/or HPV is the fact that
risk is also modified by smoking (Ang et al, 2010). Patients with
greater smoking histories appear to have their favourable out-
comes significantly tempered relative to nonsmoking HPV/p16-
positive oropharynx cases for reasons that are not explained by the
biomarker staining alone. Ang et al (2010) documented at least
30% chance of death at 3 years for HPV-positive patients with
positive smoking histories. There is little question that HPV-
positive/p16 positive nonsmoking patients have more favourable
outcomes. However, in patient populations with high or modest
smoking rate, it is still valuable to assess patients’ survival beyond
HPV status. A biomarker that more precisely captures the biology
of both smoking and tumour site, and that unifies the frequent
discrepancies between HPV staining and p16 staining would be
welcome. Recently, our group reported that p16 staining was
prognostic in a set of young patients with HNSCC who were
confirmed HPV negative by PCR and in situ hybridisation, (Harris
et al, 2010b), leading us to question whether p16 alone could be
extended to evaluate risk outside the oropharynx.
Smoking and HPV infection are two important etiologies of p16
alteration in HNSCC. In HPV-infected patients, the protein RB1 is
inactivated by viral oncoprotein E7, leading to a high and nuclear
localised p16 expression (Andl et al, 1998; Wiest et al, 2002;
Li et al, 2004; Marur et al, 2010). In contrast, in situations where
p16 is retained but altered in function by mutation or other genetic
events, we may still observe modest to high p16 expression, but
with abnormal cellular localisation. In many additional smoking
patients, p16 can be lost via more deleterious genetic or epigenetic
changes, such as homozygous deletion, nonsense mutation, or
perhaps methylation and gene silencing. On the basis of these
aetiologic differences, we expected to observe distinct patterns in
p16 IHC staining. Similar hypotheses of p16’s role in prognosis
have been tested in other tumour types. For example, in high-grade
astrocytoma, a study has shown that nucleus-located p16 is
associated with better disease outcome while cytoplasmic p16
indicates worse patients’ survival (Arifin et al, 2006). In other
tumour types, including endometrial cancers, melanoma and
astrocytomas (Emig et al, 1998; Salvesen et al, 2000; Straume et al,
2000; Milde-Langosch et al, 2001; Ghiorzo et al, 2004; Arifin et al,
2006), reports also exist where p16 localisation is associated with
disease outcomes. As p16 protein functions as a cell cycle inhibitor
in the nucleus, we proposed that nuclear p16 staining and
cytoplasmic p16 staining may have a distinct prognostic effect in
HNSCC. We tested this hypothesis in a population-based patient
cohort – the Carolina Head and Neck Cancer Study (CHANCE).
METHODS
Study population
The CHANCE was a population-based case–control study of
incident HNSCC conducted from 2002 to 2006 in 46 counties in
Central and Eastern North Carolina (Divaris et al, 2010). The
subcohort of 143 patients from this study who were treated at UNC
(University of North Carolina at Chapel Hill) hospitals and had
banked tissue available were eligible. Patients with cancers of all
head and neck subsites except nasopharynx (oral cavity, orophar-
ynx, larynx and hypopharynx) were included. Treatment decisions
were recommended by the UNC Head and Neck multidisciplinary
team and based on patient age, tumour extent, site, comorbidities
and performance status. Clinical information was extracted from
patient charts. Patients who received complete medical care at
UNC were followed by retrospective review of the medical record
for outcomes including relapse and death. Patients who had
follow-up in local institutions outside UNC were followed by
requesting medical records from the local institution or in cases
where there was no return of information from the outside
institution, patients deaths were queried from the Social Security
Death Index and local obituaries in compliance with the CHANCE
study protocols. Patients without sufficient tumour sample for
p16 staining were excluded, leaving 135 patients in the analysis.
An independent UNC TMA cohort was available for validation
that our group has reported on previously (Harris et al, 2010a).
Both studies were approved by the Institutional Review Board
of the UNC.
Tissue microarray
Tissue microarrays (TMAs) were constructed using core samples
from formalin-fixed paraffin-embedded tumour blocks. Hematox-
ylin- and eosin-stained slides were reviewed by two pathologists
(KF and WF) to confirm the original diagnosis. About 1-mm
microarray blocks were constructed on a manual tissue micro-
arrayer-1 from Beecher Instruments (Sun Prairie, WI, USA) in
triplicate. Sequential 4-mm sections were cut from each TMA.
Sectioned slides were coated in paraffin and stored at 4 1C until
staining. A second confirmatory tissue resource was also used for
the current analysis the construction and results of which have
been previously reported (Harris et al, 2010a). Briefly, a TMA
(designated young nonsmoking oral cavity cohort (YNOCC)) was
constructed in a similar manner as above that included a cohort of
42 HNSCC between the age of 18 and 39. Processing of tissue and
reagents is otherwise consistent with the current methods.
p16 IHC staining
p16 IHC staining was carried out in the Bond Autostainer (Leica
Microsystems Inc, Norwell, MA, USA) according to the manu-
facturer’s IHC protocol. Slides were put in a 601 oven to remove
excess paraffin. Slides were then placed in the autostainer and
dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond
Wash solution (AR9590). Antigen retrieval was performed for
30 min at 100 1C in Bond-Epitope Retrieval solution 1 (pH 6.0,
AR9961). Slides were then incubated with p16INK4a antibody
(mouse monoclonal anti-p16 antibody (MAB4133), Chemicon
International Company/Millipore Corporation, Temecula, CA,
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USA) for 15 min. Antibody detection was performed using the
Bond Polymer Refine Detection System (DS9800). Stained slides
were dehydrated and coverslips added. Immunohistochemical
staining was performed in the Translational Pathology Lab at UNC.
After completion of IHC, slides are stored at room temperature in
our laboratory and a virtual scanned copy of all TMA slides will be
kept for further reference.
HPV in situ hybridisation
HPV in situ hybridisation was carried out in Ventana Benchmark
XT autostainer. Slide deparaffinisation, conditioning, and staining
with INFORM HPV III Family 16 Probe (B; Ventana Medical
Systems, Tucson, AZ, USA) were performed on the autostainer
according to the manufacturer’s protocol. The probes have
affinities to HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58
and 66. Slides were scored as positive for HPV if a punctate or
diffuse pattern of signal was observed in the tumour nuclei.
p16 protein expression
p16 expression was assessed by pathologists who were blinded
as to the clinical data for the patients. The CHANCE TMA and
the YNOCC TMA were read by two pathologists (KF and LT,
respectively), with any indeterminate scores evaluated by a third
pathologist (WF). Digital images of cells were captured (magni-
fication  200) using the Aperio Scanscope (Aperio Inc., Vista,
CA, USA). Tissue samples previously shown to be p16 over-
expressors (endometrium) were used as a positive control for
intensity scoring. Each sample was given a cytoplasmic intensity
score and nuclear intensity score on a scale of 0–3, with intensity
scored 0 equal to no staining; 1, faint or focal cytoplasmic staining;
2, moderate, diffuse staining; and 3, intense and diffuse staining.
The percentage of tumour cells with positive nuclei was
determined by scoring 10 microscopic fields of 100 tumour cells
each. A semiquantitative percentage score was generated for the
cytoplasm and nucleus staining for each specimen, ranging from 0
to 100. The TMA was constructed with the goal to obtain three
cores per patient block. Not every block had sufficient tissues and
some cases resulted with only one or two cores. For samples that
had multiple cores, mean intensity or percentage scores across the
cores were used as the final intensity or percentage score for that
sample. A composite product score was calculated by multiplying
the mean intensity score and mean percentage score in the
cytoplasm or nucleus. Based on a bimodal distribution of the
scores in oropharynx patients (dark grey in Figure 2), a nuclear
product score of 100 was used as a cutoff for nuclear staining. The
75% percentile of cytoplasmic staining (133.4) was considered to
be a cutoff for cytoplasmic staining. All samples that had high
nuclear (HN) staining also had high cytoplasmic staining, resulting
in three categories in total. Patients with a nuclear product score
X100 were considered high nuclear staining (HN). Patients with a
product score at or above the 75th percentile of the cytoplasmic
score (133.4) were considered high cytoplasmic staining (HC) if
they were not in the HN group. Patients who failed to meet criteria
either for high nuclear or high cytoplasmic score were categorised
in the low staining group (LS). Based on this empirical separation,
the patients were divided into three groups; high nuclear, high
cytoplasmic staining (HN), high cytoplasmic, low nuclear staining
(HC) and low nuclear and cytoplasmic staining (LS).
Statistical analysis
All statistical analysis was performed using the R 2.9.2 software
(http://cran.r-project.org). Baseline characteristics of patients from
each group (HN, HC and LS) were compared using Fisher’s exact
test for categorical variables and one-way analysis of variance for
continuous variables. Overall survival was calculated as the time
from diagnosis date to death date or the last documented follow-up
date. Progression-free survival (PFS) was defined as the time from
diagnosis date to the date of disease progression or the last
documented follow-up date or death date from any cause. Disease
progression was defined as any documented tumour progression
(local or distant) as indicated in the clinical record. All observa-
tions were censored at 60 months. Survival curves were calculated
using the Kaplan–Meier method and compared nonparametrically
using the log-rank test. Cox proportional hazard model was used to
estimate the hazard ratio between different p16 staining groups,
adjusting for patient alcohol consumption status, tumour stage,
tumour site and HPV staining. All statistical tests were two sided
with a significance level of 0.05 and all reported confidence intervals
(CIs) were constructed at a two sided 95% confidence level.
RESULTS
Patient characteristics
A total of 143 patients were identified during the study period, of
which 135 had sufficient tumour samples for p16 staining. The
median follow-up time for these patients was 6.67 years, with only
five patients lost to follow-up before 5 years. The baseline
characteristics for these patients were summarised in Table 1.
The median age of patients at diagnosis was 57 (range 20–82). In
all, 68.9% of the patients were males, which is comparable to the
national average (Ries et al, 2007). Most patients had smoking
histories and/or alcohol use with only 12 (9%) never smokers and
44 (B30%) never drinkers. Furthermore, all of the 123 smokers,
except 2, had smoked X10 pack years. Approximately 30% of the
patients received single-modality treatment with surgery or
radiation alone. Other patients received a combination of different
treatment methods. In all, 16 (11.9%) patients were detected as
HPV positive, of which 14 had oropharyngeal tumours and the
other 2 had tumours in the oral cavity.
p16 expression
In the sample set p16 showed baseline cytoplasmic and nuclear
staining in at least one of the three cores for every patient.
Examples of IHC images of p16 staining are shown in Figure 1.
Overall, oropharyngeal cancers and HPV-positive cancers had
stronger p16 staining in both the cytoplasm and nucleus compared
with tumours of other types (Figure 2). The median nuclear
product score was 22 in oropharyngeal tumour samples compared
with 0 in non-oropharyngeal samples (permutation test of equal
density P-value o0.001). The median cytoplasmic product score
was 150 in oropharyngeal tumour samples compared with a
median product score of 38 in non-oropharyngeal samples
(permutation test of equal density P-value o0.001). A total of 9
patients had high nuclear and high cytoplasmic p16 staining (HN),
25 patients had HC and 101 had low p16 staining (LS). There was
no significant difference in age, gender, smoking status, T stages
and clinical stages between different staining groups. However,
patients with high nuclear or cytoplasmic p16 staining have more
oropharyngeal tumours and earlier nodal stage (N0–N1) compared
with the low p16 staining group.
HPV in situ hybridisation
Table 2 summarised the distribution of tumour sites with respect
to HPV positivity and smoking status. Overall, 16 of the 143
patients stained positively for HPV, with 14 of them having
tumours in the oropharynx and 2 in the oral cavity. The HPV
positivity rates were lower than some of the clinical trials and other
university based reports (Chuang et al, 2008; Fakhry et al, 2008),
due to, at least in part, the very high smoking rate in our study
population (D’Souza et al, 2007; Ang et al, 2010). In all, 37%
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Table 1 Patient characteristics by p16 staining
p16 Staining groups
Characteristics All patients (column %) HN (column %) HC (column %) LS (column %) P-values
No. of patients 135 9 25 101
Age
Median 57 56 54 58 0.14
Range 20–82 20–66 34–79 24–82
Gender
Male 93 (68.9) 8 (88.9) 19 (76) 66 (65.3) 0.28
Smokinga 123 (91.1) 7 (77.8) 22 (88) 94 (93.1) 0.16
Mean pack years (s.d.)a 39.8 (25.9) 41.4 (39.1) 38.0 (26.0) 40.0 (24.7) 0.93
Alcohola 91 (67.4) 6 (66.7) 18 (72) 67 (66.3) 0.90
T stagea
T1–T2 65 (48.1) 4 (44.4) 10 (40) 51 (50.5) 0.65
T3–T4 70 (51.9) 5 (55.6) 15 (60) 50 (49.5)
Nodal stagea
N0–N1 79 (58.5) 4 (44.4) 8 (32) 67 (66.3) 0.004
N2–N3 56 (41.5) 5 (55.6) 17 (68) 34 (33.7)
Stage
Stage I–II 43 (31.9) 1 (11.1) 5 (20) 37 (36.6) 0.12
Site
Oropharynx 38 (28.1) 7 (77.8) 15 (60) 16 (15.8) o0.001
Larynx 35 1 (11.1) 1 (4) 33 (2.7)
Oral cavity 54 (40) 1 (11.1) 6 (24) 47 (46.5)
Hypopharynx 8 (5.9) 0 3 (12) 5 (5.0)
HPV positive 16 (11.9) 3 (33.3) 10 (40.0) 3 (3.0) o0.001
Abbreviations: HC¼ high cytoplasmic, low nuclear staining; HN¼ high nuclear, any cytoplasmic staining; LS¼ low nuclear, low cytoplasmic staining. aNumbers do not sum to the
total because of missing data.
100m
Figure 1 Representative examples of p16 immunostaining in HNSCC. IHC staining for p16 expression of HNSCC was evaluated by product scores in
different cellular compartments separately. From the above left: (A) p16 high expression in both the nuclei and cytoplasm; (B) p16 low expression in both
the nuclei and cytoplasm; (C) high nuclear expression and modest cytoplasmic staining (however, by our scoring this still qualified at the lowest end of ‘high
cytoplasmic’); and (D) high cytoplasmic expression and low nuclear expression.
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(14/38) of oropharyngeal tumours were stained HPV positive in
this study, comparable to previous reports such as RTOG 9003
(Gillison et al, 2012), which reported 39% HPV positive in
oropharyngeal cancers. Human papilloma virus-positive staining
outside oropharyngeal tumours was rare, which is consistent with
the general acceptance of a low rate of HPV infection outside the
oropharynx (Begum et al, 2007). The vast majority of these HPV-
positive patients were heavy smokers: 13 of the 16 HPV-infected
patients had long histories of smoking, with a minimum of 18 pack
years. Human papilloma virus infection has been strongly
associated with both cytoplasmic and nuclear p16 positivity. All
but three HPV-positive patients were categorised as having high
nuclear or high cytoplasmic p16 expression.
Survival analysis
In the full cohort, the 3-year OS was 63.0% (95% CI: 55.3%–71.7%)
and the 3-year PFS rate was 54.1% (95% CI: 46.3%–63.2%).
Only one death occurred in the HN group during the follow-up.
In the LS group, the 3-year OS and PFS was estimated as 65.3%
(95% CI: 56.7%–75.3%) and 54.5% (95% CI: 45.6%–65.1%) using
the Kaplan–Meier method. The 3-year OS and PFS was estimated
as 40% (95% CI: 24.7%–64.6%) and 36% (95% CI: 21.3%–60.7%),
respectively, in the HC group (Figure 3). The 3-year OS and PFS
in the HN group was 100% with CI not evaluable. Both OS and
PFS results were significantly different between staining groups
with a log-rank test P-values of 0.006 and 0.009, respectively.
There is no significant difference in OS or PFS between the
HPV-positive group and HPV-negative group (P¼ 0.509 and 0.434,
respectively).
Cox proportional hazard model was used to assess the relation-
ship between each variable with OS and PFS (Table 3). p16
expression status was significantly associated with both OS and
PFS. The HN group had the best OS outcome and the lowest
hazard ratio compared with the other groups. Similar results were
obtained for PFS, although the difference was not statistically
significant. Using the HC group as a reference, the hazard ratio for
OS was 0.50 (95% CI: 0.29–0.88) for the LS group and 0.10 (95% CI:
0.013–0.75) for the HN group. Similarly, the hazard ratio for PFS
was 0.61 (95% CI: 0.35–1.04) in the LS group and 0.09 (95% CI:
0.012–0.67) in the HN staining group. If we consider local recur-
rence and distant recurrence separately, the 3-year local recurrence
rates were 24% and 26.7% for the HC and LS group, respectively,
and the 3-year distant recurrence rate was 16.0% and 10.9% for the
HC and LS group, respectively. The HN group had no recurrence
during 3 years of follow-up. When nuclear staining and cytoplasmic
staining were considered separately for their association with OS
or PFS, high nuclear staining was significantly associated with PFS
(HR¼ 0.13, 95% CI: 0.018–0.96) and insignificantly associated with
OS (HR¼ 0.17, 95% CI: 0.024–1.24). Cytoplasmic staining was not
significantly associated with either OS or PFS. In addition to p16
staining status, T3–T4 tumour stage was significantly associated
with increased risk of mortality (P-value¼ 0.009). Nodal stages
showed borderline significance in affecting OS (P-value¼ 0.07).
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Figure 2 Distributions of p16 staining product scores.
Table 2 p16 expression by smoking status and tumour site
p16 Expression HN HC LS
Smokers
HPV negative 4 (1 OC, 3 OP) 14 (5 OC, 1 LA,
3 HY, 5 OP)
92 (40 OC,33 LA,
3 HY, 16 OP)
HPV positive 3 (OP) 8 (OP) 2 (1 OC, 1OP)
Nonsmokers
HPV negative 2 (OP) 1(OC) 6 (5 OC, 1 OP)
HPV positive 0 2 (OP) 1 (1 OC)
Abbreviations: HC¼ high cytoplasmic, low nuclear staining; HN¼ high nuclear, any
cytoplasmic staining; HPV¼ human papillomavirus; HY¼ hypopharynx; LA¼ larynx;
LS¼ low nuclear, low cytoplasmic staining; OC¼ oral cavity; OP¼ oropharynx.
p16 mislocation in head and neck cancer
N Zhao et al
486















No variable tested except p16 expression status showed significant
association with PFS.
Multivariable Cox proportional hazard model showed that p16
expression status was still significantly associated with both OS
and PFS (Table 4) after adjusting for tumour site, nodal stage,
tumour stage, HPV staining and drinking pattern. Both the LS
group and the HN staining group had significantly lower hazard
than the HC staining group. Subset analysis was carried out for
oropharynx patients: after controlling for tumour stages, HPV
staining and drinking status, the hazard ratio of OS for LS and HN
groups are 0.40 (P¼ 0.18) and 0.12 (P¼ 0.06), respectively, and the
hazard ratio of PFS for LS and HN groups are 0.61 (P¼ 0.43) and
0.12 (P¼ 0.06), respectively, using the HC group as reference.
Subset analysis for other tumour sites was not conducted because
of the small number of patients.
Independent confirmation in second cohort
Using data from the YNOCC TMA, we were able to obtain p16
staining on an additional 42 samples, with 30 from the oral cavity,
6 from the oropharynx, 5 from the larynx and 1 from the
hypopharynx. This is a cohort of younger patients who were
diagnosed between the age of 20 and 39, with 23 males, 29 with
smoking history (median pack year 14.5) and 18 with alcohol
consumption history. Previously we had reported a favourable
overall outcome for those patients in the cohort who were p16
positive. At that time, we had not evaluated the independent
contribution of nuclear staining to outcomes. In this study, we
evaluated those patients by the same product score cutoff as an
independent validation. The patients were then grouped using the
same criteria for this study: 14 patients were placed in the HN
group, 4 patients in the HC group and 24 patients in the LS group.
Although P-values are not statistically significant owing to the
small sample size, strikingly, the HN staining group had superior
PFS compared with the other two groups, with similar magnitude
to our observations in the CHANCE data set. The hazard ratio of
having a recurrence in the HN group and LS group are 0.38 (95%
CI: 0.092–1.62) and 0.71(95% CI: 0.20–2.52) compared with the HC
staining group (P¼ 0.34).
DISCUSSION
The management of squamous cell carcinoma of the head and neck
appears to be at a crossroads, with the possibility that the field may
change long held treatment standards based on observations
related to the staining for the biomarkers HPV and p16. Pivotal
studies have documented significantly improved outcomes for
patients staining positively for these markers, yet a closer look
at how these biomarkers relate to each other has stimulated
researchers to look for the mechanisms behind the beneficial
outcome association. First, it is clear that mechanisms in addition
to HPV infection itself are at work as evidenced by the modulation
of risk caused by smoking. There is also at least circumstantial
evidence that alterations of p16, independent of HPV, may convey
some of the favourable prognoses seen in HNSCC patients that
cannot simply be ascribed to false negative HPV assays. Evidence
from tumours outside the head and neck lead us to consider
nuclear localisation of p16 as a novel biomarker. In this report, the
results comparing nuclear localisation of p16 to cases where p16 is
excluded from the nucleus warrant further study. Furthermore, the
results may help suggest a mechanistic role for this biomarker that
go beyond an empiric view of p16 as a proxy for HPV of use
limited to the oropharynx.
To consider p16 status (as indicated by p16 staining) as a
mechanistic marker requires a review of the ways that p16 is
altered in cancer. In the case of HPV, p16 overexpression is a result
of expression of HPV-derived oncoproteins E6 and E7 and can
functionally inactivate the p53 and pRb tumour-suppressor
protein, resulting in a downregulation of p53, pRb and a strong
upregulation of p16 at the molecular level (Andl et al, 1998; Wiest
et al, 2002; Li et al, 2004; Marur et al, 2010). One could think of p16
expression in the context of HPV infection as a proxy for multiple
genotypes that would generally be considered favourable for
cancer prognosis (p53 wild type (WT), Rb WT and p16 WT).
However, in the more common setting of tumours, p16 is lowly
expressed, possibly by less favourable genetic or epigenetic
changes, such as homozygous deletion of p16, nonsense mutation,
or perhaps methylation and gene silencing. In those situations,
where there are more deleterious mutations such as loss of Rb
or perhaps amplification of cyclin D1 (common in HNSCC), the
tumours can express high levels of p16 with no inhibition of cell
cycling. In these situations, nuclear trafficking might be altered
and high p16 expression might indicate particularly unfavourable
cancer biology. Smoking could be the means of inactivation of
genes downstream of p16 without requiring p16 loss as the disease
modifying event associated with worse outcome. To evaluate such
an explanation, we attempted to sequence p16 and other targets in
the current sample set but were unsuccessful because of the quality
of the DNA in these paraffin-embedded specimens.
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Figure 3 Kaplan–Meier estimates of overall survival (A) and progression
free survival (B) according to p16 expression in whole study population. All
survival estimates were censored at 60 months. Abbreviations: HC¼ high
cytoplasmic, low nuclear staining; HN¼ high nuclear, any cytoplasmic staining;
LS¼ low nuclear, low cytoplasmic staining. ‘þ ’ censored observations.
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To our knowledge, no previous study has investigated how
different p16 expression localisation can be related to disease
outcomes in HNSCC despite evidence that differential staining
patterns similar to what we describe have been shown to be
relevant in other tumours, including endometrial cancers,
melanoma and astrocytomas (Emig et al, 1998; Salvesen et al,
2000; Straume et al, 2000; Milde-Langosch et al, 2001; Ghiorzo
et al, 2004; Arifin et al, 2006). Most strikingly, familial melanoma
studies strongly support our hypothesis because of the associated
point mutations and the failure to localise p16 to the nucleus
(Ghiorzo et al, 2004). In this report, patients without the germline
variant displayed a combined nuclear and cytoplasmic staining.
The authors demonstrated that p16 mutations in these melanoma
patients may impair the cytoplasmic–nuclear shuttling similar to
BRCA1 where BRCA1 is shifted to the cytoplasm because of a
mutation in nuclear localisation signals and the HN2-terminal
(Fabbro et al, 2004; Ghiorzo et al, 2004; Arifin et al, 2006).
This study has limitations and suggests that further evaluation
of p16 nuclear staining is warranted. Most notably, the current
study is relatively small and includes a large number of smokers.
Similarly, because of the retrospective nature of the current study,
patients are heterogeneous in stage, site, treatment and other
Table 3 Univariate analyses of prognostic factors for overall or PFS
PFS OS
Characteristics No. of events PYs HR 95% CI P-value No. of events PYs HR 95% CI P-value
Age (years)
X57/o57 38/34 228/197 0.97 0.61–1.55 0.91 33/28 254/224 1.03 0.62–1.70 0.92
Smoker/nonsmoker 66/6 385/41 1.19 0.52–2.74 0.69 56/5 433/45 1.19 0.48–2.97 0.71
Drinking 53/19 270/154 1.55 0.92–2.62 0.10 45/16 305/174 1.61 0.91–2.84 0.10
Site
Larynx 18 111 1.17 0.61–2.25 0.63 14 134 1.01 0.49–2.10 0.97
Oral cavity 29 166 1.27 0.71–2.29 0.42 26 179 1.40 0.74–2.64 0.30
Hypopharynx 7 15.4 2.74 1.14–6.60 0.02 6 20 2.70 1.04–6.99 0.04
Oropharynx 18 131 1.0 (Reference) 15 145 1.0 (Reference)
T stage
T3–T4/T1–T2 42/30 202/221 1.49 0.93–2.38 0.10 39/22 220/258 2.02 1.20–3.41 0.009
N stage
N2–N3/N0–N1 31/41 165/259 1.16 0.73–1.86 0.52 30/31 177/301 1.61 0.97–2.65 0.07
Stage
Late(III–IV)/early(I–II) 52/20 281/144 1.29 0.77–2.17 0.33 47/14 309/169 1.79 0.98–3.25 0.06
p16: Combined nuclear and cytoplasmic staining
HN 1 45 0.09 0.012–0.67 0.067 1 45 0.10 0.013–0.75 0.025
LS 53 319 0.61 0.35–1.04 0.019 43 365 0.50 0.29–0.88 0.017
HC 18 61 1.0 (Reference) 17 68 1.0 (Reference)
HPV
± 7/65 55/368 0.73 0.34–1.60 0.44 6/22 60/418 0.75 0.32–1.75 0.51
Abbreviations: CI¼ confidence interval; HC¼ high cytoplasmic, low nuclear staining; HN¼ high nuclear, high cytoplasmic staining; HR¼ hazard ratio; LS¼ low nuclear,
low cytoplasmic staining; OS¼ overall survival; PFS¼ progression-free survival; PYs¼ person-years.
Table 4 Multivariate analysis of prognostic factors for survival or PFS
PFS OS
HR 95% CI P-values HR 95% CI P-values
T3–T4/T1–T2 1.32 0.77–2.26 0.31 1.72 0.94–3.12 0.08
N2–N3/N0–N1 0.96 0.55–1.68 0.90 1.24 0.68–2.28 0.48
Drinking 1.37 0.76–2.49 0.29 1.21 0.64–2.31 0.56
Site
Larynx 1.29 0.57–2.89 0.54 1.34 0.54–3.30 0.53
Oral cavity 1.35 0.66–2.78 0.41 1.65 0.75–3.60 0.21
Hypopharynx 1.73 0.66–4.56 0.27 1.69 0.59– 4.84 0.33
Oropharynx 1 (Reference) 1 (Reference)
p16 Staining
HN 0.092 0.01–0.71 0.02 0.10 0.01–0.78 0.03
LS 0.475 0.24–0.95 0.03 0.37 0.18–0.75 0.01
HC 1 (Reference) 1 (Reference)
HPV positives 0.65 0.24–1.81 0.41 0.54 0.179–1.61 0.27
Abbreviations: CI¼ confidence interval; HC¼ high cytoplasmic, low nuclear staining; HN¼ high nuclear, high cytoplasmic staining; HR¼ hazard ratio; LS¼ low nuclear,
low cytoplasmic staining; OS¼ overall survival; PFS¼ progression-free survival.
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factors that might impact risk in ways that have not been
appreciated. However, the prognostic effect of p16 localisation
remained significant after controlling for these factors. The
validation cohort provided extra support for our result. We do
provide evidence regarding the use of p16 in nonsmokers with
the YNOCC cohort, because this group does not include significant
numbers of nonsmoking HPV-positive patients. However, because
most HNSCC patients are still smokers despite the rising numbers
of nonsmoking patients, these data are applicable to a larger
portion of HNSSC patients. Finally, our cutoff for different p16
groups was based on the empirically observed distributions of p16
staining in oropharynx vs non-oropharynx samples. This cutoff
was neither optimised nor cross-validated and cannot be directly
used for clinical settings.
In conclusion, we have provided a preliminary investigation into
the nuclear staining of p16 as a critical factor in the complex set of
conditional biomarkers including HPV, smoking, oropharyngeal
carcinomas and nonlocalised staining of p16. This biomarker, if
validated, is already widely available and could potentially impact
clinical care of HNSCC.
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